Bookmark and Share

Deanna L. Kelly

Deanna L. Kelly Pharm.D., BCPP

Academic Title: Professor
Primary Appointment: Psychiatry
Location: MPRC, Treatment Research Program
Phone: (410) 402-6861
Phone: (410) 402-6860
Fax: (410) 402-6880

Personal History:

Dr. Kelly received her Bachelor of Science and Doctorate in Pharmacy at Duquesne University in Pittsburgh, PA. She completed residency training in psychiatric pharmacy practice at the University of Maryland in 1997 and became board certified in psychiatric pharmacy practice in 1998. Dr. Kelly is currently the Director of the Treatment Research Program (TRP) and the Brief Stay Unit (BSU) at the Maryland Psychiatric Research Center (MPRC).

Dr. Kelly is currently a member of the Department of Health and Mental Hygiene Institutional Review Board, she is the Chair of the Junior Faculty Mentoring Committee, serves on the Department of Psychiatry Appointment and Promotions Committee and mentors a host of students and residents.

Dr. Kelly has authored three editions of the book entitled "Pharmacologic Treatment of Schizophrenia." She also authors the Schizophrenia chapter for "Pharmacotherapy, Principles and Practice." Additionally, she has received the National Institute of Mental Health New Investigator Award and the International Congress on Schizophrenia Research Young Investigator Award. She is the Associate Editor for Clinical Schizophrenia and Related Psychoses. She also serves as Guest Editor for Schizophrenia Bulletin and has reviewed for over 30 psychiatry journals including Archives of General Psychiatry, American Journal of Psychiatry, Journal of Clinical Psychiatry, Schizophrenia Research and Psychiatric Services. She is a full member of the American College of Neuropsychopharmacology (ACNP) and is currently active in the College of Psychiatric and Neurologic Pharmacists (CPNP) where she currently serves as Program Chair for the 2014 Meeting. She has given over 100 invited lectures and locally serves in her community.

Research Interests:

Dr. Kelly has been involved in several clinical trials for the treatment for schizophrenia and has been active in psychopharmacology research for the past 16 years. She has had continuous funding from NIH for the past decade and has led many clinical studies. Her research interests are in the area treatment research that can impact the lives of people with schizophrenia. She has been funded to examine the effects of antipsychotics and substance abuse/nicotine on mortality in schizophrenia and has served as Principal Investigator on a large 7 year contract with the National Institutes on Drug Abuse (NIDA) Intramural Research Program. She currently is working conjunction with others on a few phase I studies for safety testing of new medications for drug abuse. She has evaluated many novel medications and strategies in schizophrenia, most recently completing a clinical trial with adjunctive minocycline, an antibiotic with anti-inflammatory properties. She just received funding to study a gluten free diet in patients who are positive for antigliadin antibodies, a possible biomarker for efficacy in this subpopulation.

In addition, she has an interest and track record in women’s mental health where she currently is funded to look at the effects of novel treatments on symptomatic hyperprolactinemia. She is also examining the effects of estrogen on women across the life cycle and the effects of childhood trauma on symptoms in women.

Lastly, a major focus of her research is with the medication clozapine. She has been a proponent for more widespread use and currently is working on understanding barriers to current use, develop monitoring devices and study ways to better deliver treatment. She has a history in studying side effects and efficacy in numerous clinical studies with clozapine.


Peer Reviewed Book Chapters

  • Conley RR, Kelly DL. Pharmacologic treatment of schizophrenia. Professional Communications, Inc. First Edition, Caddo, OK 2000.
  • Conley RR, Kelly DL. Pharmacologic treatment of schizophrenia. Professional Communications, Inc. Second Edition, Caddo, OK 2003.
  • Conley RR, Kelly DL. Pharmacologic treatment of schizophrenia. Professional Communications, Inc. Third Edition, Caddo, OK, 2007.
  • Conley RR, Kelly DL. The long-term efficacy, effectiveness and safety of second-generation antipsychotic drugs. In: Atypical antipsychotics: from bench to bedside. Editors: Csernansky JG, Lauriello J. Marcel Dekker 2004.
  • Conley RR, Kelly DL. Schizophrenia. In Conn’s Current Therapy 2005. Editors: Rakel R and Bope E. Philadelphia, PA: W.B. Saunders, Philadelphia 2005, pp. 1280-1284.
  • Conley RR, Kelly DL. Schizophrenia. In Conn’s Current Therapy 2006. Editors: Rakel R and Bope E. Philadelphia, PA: W. B. Saunders, Philadelphia 2006, 1370-1374.
  • Boggs D, Kelly DL, Conley RR. Antipsychotic Therapeutics (Efficacy and Side Effects). In The Year in Schizophrenia Volume I. Editors: Thaker G, Carpenter WT., Clinical Publishing, Oxford, UK. 2007,209-231.
  • Kelly DL, Weiner E. Schizophrenia, in Pharmacotherapy Principles and Practice, Chisholm-Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2008.
  • Kelly DL, Boggs DL, Conley RR. Reaching for wellness in schizophrenia: A Complex Disease Necessitating Complex Care. Psychiatric Clinics of North America, Buckley PF, Messias EL (eds), Saunders, Philadelphia, PA 2007;30:453-479.
  • Boggs D, Kelly DL. Antipsychotic Therapeutics. In The Year in Schizophrenia Volume II. Editors: Thaker G, Carpenter WT., Clinical Publishing, Oxford, UK. 2008.
  • Wehring HJ, Kelly DL. Sexual Dysfunction in Schizophrenia. In: Medical Illness in Schizophrenia, second edition 2009. Eds Meyer JM, Nasrallah HA. American Psychiatric Publishing, Inc.
  • Kelly DL, Weiner E, Wehring H. Schizophrenia, in Pharmacotherapy Principles and Practice, second edition. Chisholm-Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2010.
  • Perez G, Dixon L, Kelly DL. Evidence Based Medicine. In: Levin BL, Becker MA (Eds.). A Public Health Perspective of Women's Mental Health. New York: Springer, 2010.
  • Kelly DL, Buchanan RW. Clozapine: It’s Current Status In and Beyond Treatment Resistant Schizophrenia. In: Therapeutic Strategies in Schizophrenia. 2010. Eds., P McKenna, A. Mortimer. Clinical Publishing Limited.
  • Wehring HJ, Kelly DL. Schizophrenia. In; Pharmacotherapy Principles & Practice Study Guide: A Cased Based Care Plan Approach, First Edition. Michael D. Katz, Kathryn R. Matthias, and Marie A. Chisholm-Burns, Editors. The McGraw-Hill Companies, Inc. 2010.
  • Kelly DL, Weiner E, Wehring H. Schizophrenia, in Pharmacoherapy Principles and Practice, third edition, Chrisholm, Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2012.
  • Kelly DL, Weiner E, Wehring H. Schizophrenia, in Pharmacotherapy Principles and Practice, third edition, Chrisholm, Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2014

Peer-reviewed journal articles

  • Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR. Rehospitalization rates of depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. American Journal of Health-Systems Pharmacy. 1998;55(4):17-19. PMID: 987268.
  • Sherr JD, Kelly DL. Substitution of immediate release valproic acid for divalproex sodium for adult psychiatric inpatients. Psychiatric Services. 1998;49:1355-57. PMID: 9779912.
  • Conley, RR, Kelly DL, Gale E. Olanzapine response in therapy-refractory schizophrenia with substance abuse. Schizophrenia Research. 1998;33:95-101. PMID: 9783349.
  • Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM. Weight gain in adolescents treated with risperidone and conventional antipsychotics. The Journal of the Child and Adolescent Psychopharmacology. 1998;8:151-159. PMID: 9853689.
  • Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed dose study. Schizophrenia Research. 1999;40(2):101-4. PMID: 10593449.
  • Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. American Journal of Psychiatry. 1999;156:863-868. PMID:10360124.
  • Conley RR, Tamminga CA, Kelly DL, Richardson C. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biological Psychiatry. 1999; 46;73-77. PMID:10394475.
  • Love RC, Conley RR, Kelly DL, Bartko JJ. A dose-outcome analysis of risperidone. J Clin Psychiatry. 1999;60:771-775. PMID: 10584767.
  • Kelly DL, Love RC. Ziprasidone and the QTc: pharmacokinetic and pharmacodynamic considerations. Psychopharmacology Bulletin. 2001;35:66-79. PMID: 12397857.
  • Richardson C, Kelly DL, Conley RR. Biperiden for excessive sweating associated with clozapine use. Am J Psychiatry. 2001;158:1329-30. PMID: 11481174.
  • Conley RC, Kelly DL. Management of treatment-resistant schizophrenia. Biological Psychiatry. 2001;50:898-911.PMID: 11743944.
  • Kelly DL, Nelson MW, Love RC, Yu Y, Conley RR. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. Psychiatric Services. 2001;52:676-8. PMID: 11331805.
  • Conley RR, Kelly DL. Current status of antipsychotic treatment. Current Drug Targets - CNS and Neurological Disorders. 2002;1:123-128. PMID:12769630.
  • Kreyenbuhl J, Kelly DL, Conley RR. Circumstances of suicide among patients with schizophrenia. Schizophrenia Research. 2002;58(2-3):253-6. PMID: 12409166.
  • McMahon RP, Kelly DL Kreyenbuhl J, Kirkpatrick B, Love RC, Conley RR. Novel factor-based symptom scores in treatment-resistant schizophrenia: implications for clinical trials. Neuropsychopharmacology. 2002;537-545. PMID: 11927178.
  • Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter WT Jr. Adverse Effects and Laboratory Parameters of High-Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia. Annals of Clin Psychiatry. 2003;15:181-6. PMID: 14971863.
  • Kelly DL, Kreyenbuhl J, Love RC, Van-Duong Q, Conley RR. Six-month review of weight and metabolic parameters in patients on clozapine, risperidone, olanzapine and quetiapine. Journal of Clinical Psychiatry. 2003;64:1133-4. PMID: 14628994.
  • Kelly DL, Gale EA, Yu Y, Conley RR. Clozapine treatment in patients with prior substance abuse. Canadian Journal of Psychiatry. 2003;48(2):111-4.
  • Kelly DL, Conley RR. Evaluating sexual function in patients with treatment-resistant schizophrenia. Schizophrenia Research. 2003;63(1-2):195-6. PMID: 12892874.
  • Wehring H, Kelly DL, Love RC, Conley RR. Deaths from diabetic ketoacidosis after long-term clozapine treatment. Am J Psychiatry. 2003;160:2241-2242. PMID:14638600.
  • Lambert TJR, Cock N, Alcock S, Kelly DL, Conley RR. Measurement of antipsychotic-induced side effects: Support for the validity of a self-report (LUNSERS) vs. structured interview (UKU) approach to measurement. Human Psychopharmacology. 2003;18(5):405-41. PMID:12858330.
  • Nelson M, Reynolds R, Kelly DL, Conley RR. Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone: case report. Clinical Neuropharmacology. 2003;26:297-8. PMID: 14646608.
  • Conley RR, Kelly DL, Love RC, McMahon RP. Rehospitalization risk with second-generation and depot antipsychotics. Annals of Clinical Psychiatry. 2003. 15:23-31. PMID:12839430.
  • Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr. The Efficacy of High Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia: A Double-Blind Crossover Study. J Clin Psychopharmacology. 2003;23:668-671. PMID: 14624201.
  • Lambert TJ, Brenan A, Castle DJ, Kelly DL, Conley RR. Perception of depot antipsychotics by mental health professionals. J Psychiatric Practice. 2003;9(3):252-260. PMID: 15985940.
  • Love RC, Kelly DL. Olanzapine and risperidone. American Journal of Health-Systems Pharmacy. 2003;60:487-88. PMID: 12635459.
  • Shim J-C, Kelly DL, Kim Y-H, Yoon Y-R, Park JH, Shin J-G, Conley RR. Fluoxetine augmentation of haloperidol in chronic schizophrenia. J Clin Psychopharmacology. 2003; 520-2. PMID:14520132
  • Lambert, TJ, Kelly DL, Alcock S, Conley RR. Psychotropic prescribing for acute inpatient admissions in patients with severe psychosis. J Clin Psychopharmacology. 2004;24:91-3. PMID: 14709954
  • Kelly DL, Conley RR. Sexuality and schizophrenia: a review. Schizophrenia Bulletin: 2004;30:767-779. PMID:15954189
  • Kelly DL, Shim J-C, Feldman SM, Yu Y, Conley RR. Lifetime Psychiatric Symptoms in Persons with Schizophrenia Who Died by Suicide Compared to Other Means of Death. J of Psychiatric Research. 2004;38:531-36. PMID:15380404
  • Kelly DL, Love RC, Mackowick M, Conley RR. Atypical Antipsychotic Use in a State Hospital Inpatient Adolescent Population, Journal of Child and Adolesc Psychopharmacology. 2004; 14(1):75-85. PMID:15142394
  • Conley RR, Kelly DL, Beason-Held, Holcomb H, Richardson C, Tamminga CA, Carpenter WT. The effects of clozapine and high dose olanzapine on brain function in treatment-resistant schizophrenia: a case study. Journal of Psychopharmacology. 2004;18:429-31. PMID:15358989
  • Kim YH,Shim J-C, Kelly DL, Lee J-G, Seo Y-S, Conley RR. Cortisol Response to Buspirone in Extended Abstinent Alcoholics. Alcohol and Alcoholism. 2004;39(4):287-289. PMID:15208158
  • Conley RR, Shim JC, Kelly DL, Yu Y, Feldman S, McMahon RP. Cardiovascular disease in Relation to Weight in deceased persons with schizophrenia. Comprehensive Psychiatry. 2005;46:460-7. PMID:16275214
  • Conley RR, Kelly DL. Review of Current Drug Targets and Pharmacology of Antipsychotic Treatment. Medicinal Chemistry Reviews- Online. 2005;2(3):177-182.
  • Jung DU, Seo YS, Park JH, Jeong CY, Conley RR, Kelly DL, Shim JC. The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia. J Clin Psychopharmacol 2005;25:613-615, PMID:16282852.
  • Kelly DL. The Schizophrenic Patient: The Reproductive Years and Beyond The Female Patient, OB-GYN edition, 2005;30(8):22-31.
  • Conley RR, Kelly DL. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Israel Journal of Psychiatr and Related Sciences. 2005;42(1):51-60. PMID:16134407
  • Conley RR, Kelly DL, Nelson M, Richardson CM, Feldman S, Reynolds R, Steiner P, Yu Y, Khan I, McMullen R, Gale E, Mackowick M, Love R. Risperidone and quetiapine vs. fluphenazine in treatment-resistant schizophrenia. Clinical Neuropharmacology. 2005;28(4):163-8. PMID:16062094
  • Kelly DL, Carpenter WT, Conley RR. First Episode Schizophrenia: A Focus on Pharmacologic Treatment and Safety Considerations. Drugs. 2005; 65:1113-38. PMID:15907146
  • Conley RR, Kelly DL, Lambert TJ, Love RC. A comparison of clozapine use in Maryland and in Victoria, Australia. Psychiatric Services. 2005;56:320-3. PMID:15746507
  • Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone or fluphenazine. Journal of Clinical Psychiatry. 2005;66:80-84. PMID:15669892
  • Shim J-C Kim Y-H, Kelly DL, Lee J-G, Conley RR. Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences. 2005;17:221-6. PMID:15939977
  • Kelly DL. Treatment Considerations in Women with Schizophrenia. Journal of Women’s Health. 2006;15:1132-40. PMID:17199454
  • Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR. Clozapine Underutilization and Discontinuation in African-Americans Due to Leucopenia. Schizophrenia Bulletin. 2007;33(5):1221-4. PMID:17170061
  • Kelly DL, Dixon L, Kreyenbuhl J, Lehman AF, Love RC, Medoff D, Brown C, Conley RR. Clozapine Utilization and Outcomes by Race in a Public Mental Health System: 1994-2000. J Clin Psychiatry. 2006;67:1404-11. PMID:17017827
  • Jung D-O, Conley RR, Kelly DL, Kim D_W, Yoon S-H, Jang J-H, Shin J-G, Shim J-C. The Prevalence of Bone Mineral Density Loss in the Korean Patients with Chronic Schizophrenia. J Clin Psychiatry. 2006;67:1391-96. PMID:17017825
  • Kelly DL, Richardson CM, Yu Yang, Conley RR. Plasma Concentrations of High Dose Olanzapine in a Double Blind Crossover Study. Human Psychopharmacology: Clinical and Experimental. 2006;21:393-8. PMID:16850522
  • Kelly DL, Conley RR, Feldman S, Yu Y, McMahon RP, Richardson CM. Adjunct Divalproex or Lithium to Clozapine in Treatment-Resistant Schizophrenia. Psychiatric Quarterly. 2006;77(1):81-95. PMID:16397757
  • Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology. 2006;31;340-346. PMID:16198059
  • Shim J-C, Shin J-G, Kelly DL, Jung D-U, Seo Y-S, Liu KH, Sohn J-H, Conley RR. Adjunctive Treatment With a Dopamine Partial Agonist, Aripiprazole, for Antipsychotic-Induced Hyperprolactinemia: A Placebo-Controlled Trial. American Journal of Psychiatry. 2007;164 (9):1310-2. PMID:17728426
  • Conley RR, Kelly DL. Clinical Pharmacology and Medication-Associated Side Effects: A Review of Second-Generation Antipsychotics for Schizophrenia. Clinical Schizophrenia & Related Psychoses. 2007;3:135-146.
  • Shim JC, Choe BM, Kim JG, Jae YM, Kim HC, Kim SG, Oh MK, Kelly DL, Conley RR.Discontinuation of Risperidone, Olanzapine, and Haloperidol in First Episode Psychosis. J Clin Psychopharmacol. 2007;27:400-401. PMID:17632229
  • Kelly DL, Kreyenbuhl J, Buchanan RW, Malhotra MK. Why Not Clozapine? Clinical Schizophrenia & Related Psychoses. 2007;1:92-5.
  • Conley RR, Kelly DL. Drug–drug Interactions Associated with Second-Generation Antipsychotics: Considerations for Clinicians and Patients. Psychopharmacology Bulletin. 2007;40:77-97. PMID:17285099
  • Kelly, DL, Conley RR, Love RC, Morrison JA, McMahon RP. Metabolic Risk With Second-Generation Antipsychotic Treatment: A Double-Blind Randomized 8-week Trial of Risperidone and Olanzapine. Annals of Clinical Psychiatry. 2008;20:71-8. PMID:18568578
  • Kelly DL, Weiner E, Conley RR, McMahon RP, Buchanan RW. Lack of Beneficial Galantamine Effect for Smoking Behavior: A Double-Blind Randomized Trial in People with Schizophrenia. Schizophrenia Research. 2008;103;161-8. PMID:18550339
  • Shim JC, Liu Y-S, Kelly DL. Aripiprazole Treatment Causes Extrapyramidal Side Effects but Not Prolactin Elevations: A Disconnect of the Striatal D2 Occupancy Story. J Clin Psychopharmacology. 2008;28(3):353-354. PMID:18480699
  • Boggs DL, Kelly DL, Nelson MW, Yu Y, Feldman S, McMahon RP, Conley RR. Quetipine at High doses for Treatment Refractory Schizophrenia. Schizophrenia Research. 2008;101:347-8. PMID:18281197
  • McMahon RP, Kelly DL, Boggs DL, Li L, Hu Q, Davis JM, Carpenter WT. Feasibility of Reducing the Duration of Placebo-Controlled Trials in Schizophrenia Research. Schizophrenia Bull. 2008;34:298-301. PMID:18184634
  • Boggs DL, Kelly DL, Love RC, McMahon RP, Conley RR. Comparison of Clozapine Response for Inpatients in the Research Setting versus Routine Clinical Practice. Psychiatric Quarterly. 2008;79(2):111-119. PMID:18214677
  • Schwilke EW, Schwope DM, Karschner EL, Lowe RH, Darwin WD, Kelly DL, Goodwin RS, Gorelick DA, Huestis MA. Δ9-Tetrahydrocannabinol (THC), 11-Hydroxy-THC & 11-nor-9-Carboxy-THC Plasma Pharmacokinetics During and Following Continuous High Dose Oral THC. Clinical Chemistry. 2009;55:2180-9. PMID: 19833841
  • Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Nelson M, Dickinson D, Gold JM, Ball MP, Feldman S, Liu F, Conley RR. A randomized double blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clinical Psychiatry. 2009;70(4):518-25. PMID: 19358788.
  • Kelly DL, Linthicum J, Wehring HJ, Feldman S, McMahon RP, Lover RC, Wagner T, Shim J-C, Fowler DR. Cardiac-Related findings at autopsy in people with severe mental illness treated with clozapine or risperidone. Schizophrenia Research. 2009;107:134-8. PMID:19028422
  • Conley RR, Boggs DL, Kelly DL, McMahon RP, Feldman S, Ball P, Buchanan RW. The Effects of Galantamine on Psychopathology in Chronic Stable Schizophrenia. Clinical Neuropharmacology. 2009;32;69-74. PMID:18978489
  • Kelly DL, Weiner E, Ball MP, McMahon RP, Carpenter WT, Buchanan RW. Remission in Schizophrenia: The Relationship to Baseline Symptoms and Changes in Symptom Domains During a One-Year Study. J of Psychopharmacology. 2009:23;436-41. PMID:18583442
  • Kelly DL, McMahon RP, Liu F, Love RC, Wehring HJ, Shim JC, Warren KR, Conley RR. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry. 2010;71:304-11. PMID: 20079332
  • Kelly DL, Feldman S, Boggs DL, Gale E, Richardson CM, Conley RR. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia. Comprehensive Psychiatry. 2010;51;298-302. PMID 20399340
  • Wehring HJ, Liu F, McMahon RP, Spieker EA, Warren KR, Boggs DL, Love RC, Dickinson D, Shim JC, Fowler D, Kelly DL. The relationship of brain weight to body mass index (BMI) upon autopsy in young people with severe mental illness. Schizophrenia Research. 2010;123:86-7. PMID:20800997
  • Weiner E, Conley RR, Ball MP, Feldman S, Gold JM, Kelly DL, Wonodi I, McMahon RP, Buchanan RW. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine Neuropsychopharmacology. 2010;35;2274-83. PMID: 20664583
  • Milman G, Barnes AL, Schwope DM, Schwilke EW, Darwin WD, Goodwin RS, Kelly DL, Gorelick DA, Huestis MA. Disposition of Cannabinoids in Oral Fluid Following Controlled Around-the-Clock Oral THC Administration. Clinical Chemistry. 2010;56:1261-9. PMID: 20530732
  • Levin KH, Copersino ML, Heishman SJ, Liu F, Kelly DL, Boggs DL, Gorelick DA. Cannabis Withdrawal Symptoms in Non-Treatment-Seeking Adult Cannabis Smokers. Drug and Alcohol Dependence. 2010;111:120-7. PMID: 20510550
  • Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Fischer BA, Himelhoch S, Boggs DL, Fang B, Peterson E, Aquino PR, Keller W. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophr Bull. 2010;36;71-93. PMID: 19955390
  • Warren KW, Kelly DL. Brief Psychotic Disorder. British Medical Journal Online 2011.
  • Wehring HJ, Thedford S, Koola M, Kelly DL. Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia Disease. 2011;3:107-23.
  • Jung DU, Kelly DL, Oh MK, Kong BG, Kang JW, Lee SJ, Shim JC: Bone Mineral Density and Osteoporosis Risk in Older Patients With Schizophrenia. J Clinical Psychopharmacology. 2011;31:406-10. PMID: 21694624
  • Kelly DL, Myers CS, Abrams MT, Feldman S, Park J, McMahon RP, Shim JC. The impact of substance abuse on osteoporosis screening and risk of osteoporosis in women with psychotic disorders. Osteoporosis Int. 2011;22(4):1133-43. PMID: 20533029
  • Milman G, Barnes AJ, Schwope DM, Schwilke EW, Goodwin RS, Kelly DL, Gorelick DA, Huestis MA: Cannabinoids and metabolites in expectorated oral fluid after eight days of controlled around-the-clock oral THC administration. Analytical and Bioanalytical Chemistry, 2011;401:599-607. PMID: 21637933
  • Cascella NG, Kryszak D, Bhatti B, Gregory P, Kelly DL, Mc Evoy JP, Fasano A, Eaton WW. Prevalence of celiac disease and gluten sensitivity in the United States Clinical Antipsychotic Trials of Intervention Effectiveness Study Population. Schizophr Bull. 2011;37:94-100, PMID:19494248.
  • Ball MP, Warren KR, Feldman S, McMahon RP , Kelly DL, Buchanan RW: Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses. 2011. Apr;5(1):17-25. PMID: 21459735
  • Lo S, Raley HG, Heishman SJ, Wright K, Wehring HJ, Moolchan ET, Feldman S, Liu F, McMahon RP, Richardson CM, Kelly DL. Cigarette Craving and Dependency in People with Schizophrenia Compared to Normal Controls. Schizophrenia Research. 2011;127:241-5. PMID: 20637571.
  • Kelly DL, McMahon RP, Wehring H, Liu F, Mackowick K, Boggs DL, Warren KR, Feldman S, Shim JC, Love RC, Dixon L. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bulletin. 2011;37:832-8, PMID: 20019128
  • Weiner E, Buchholz A, Coffay A, Liu F, McMahon RP, Buchanan RW, Kelly DL. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res. 2011 Jun;129(1):94-5. PMID: 21376537
  • Kelly DL, Gorelick DA, McMahon RP, Boggs DL, Linthicum J, Liu F, Feldman S, Ball MP, Richardson CM, Conley RR, Gold JM, Wehring HJ, Kearns AM, Huestis MA, Buchanan RW. Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms In Overweight People with Schizophrenia: A Randomized, Double-Blind Pilot Study, J Clinical Psychopharmacology, 2011;31:86-91 PMID: 21192149
  • Warren KR, Ball MP, Feldman S, Liu F, McMahon RP, Kelly DL. Exercise program adherence using a 5-kilometer event and an achievable goal in people with schizophrenia. Biol Res Nurs 2011;13:383-90. PMID: 21196420
  • Kelly DL, Vyas G, Richardson CM, Koola MM, McMahon RP, Buchanan RW, Wehring HJ. Adjunct Minocycline to Clozapine in Treatment Resistant Schizophrenia. Schizophrenia Research. 2011;13:257-8. PMID: 21872445
  • Gorelick DA, Goodwin RS, Schwilke E, Schwope DM, Darwin WD, Kelly DL, McMahon RP, Liu F, Ortemann-Renon C, Bonnet D, Huestis MA. Antagonist-elicited cannabis withdrawal in humans. J Clin Psychopharmacol 2011;31:603-12. PMID: 251869692
  • Kelly DL, Thedford S, Vyas G. A new blood-based diagnostic aid for schizophrenia. Psychiatr Serv 2011;62:1107. PMID: 21885596
  • Milman G, Schwope DM, Schwilke EW, Darwin WD, Kelly DL, Goodwin RS, Gorelick DA, Huestis MA. Oral fluid and plasma cannabinoid ratios afer around-the-clock controlled oral [delta]9-tetrahydrocannabinol administration. Clin Chem 2011;57:1597-606. PMID: 21875944
  • Goodwin RS, Baumann MH, Gorelick DA, Schwilke E, Schwope DM, Darwin WD, Kelly DL, Schroeder JR, Ortemann-Renon C, Bonnet D, Huestis MA. CB1-Cannabinoid receptor antagonist effects on Cortisol in cannabis-dependent men. Am J Drug Alcohol Abuse 2012;38:114-9 PMID: 2179781
  • Koola M, Fawcett JA, Kelly DL. Case report on the management of depression in schizoaffective disorder, bipolar type focusing on lithium levels and measurement based care. Journal of Nervous and Mental Disease, 2011;199:989-990. PMID: 22134460
  • Wehring HJ, Thedford S, Koola M, Kelly DL. Patient and health care provider perspectives on long acting antipsychotics in schizophrenia and the introduction of olanzapine long acting injection. J Cent Nerv Syst Dis 2011;3:107-123. PMID: 23293546
  • Jackson J, Eaton W, Cascella N, Fasano A, Kelly DL. Neurologic and Psychiatric Manifestations of Celiac Disease and Gluten Sensitivity. Psychiatric Quarterly. 2012;83:91-102. PMID: 21877216.
  • Boggs DL, Kelly DL, RP McMahon, Gold JM, Gorelick DA, Linthicum J, Conley RR, Liu F, Waltz J, Huestis MA, Buchanan RW. Rimonabant for neurocognition in schizophrenia: a 16 week double blind randomized placebo controlled trial. Schizophr Res, 2012;134:207-10. PMID: 22137462
  • Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, Lee SW, Kong BG, Kang JW, Oh MK, Kim SD, McMahon RP, Kelly DL. Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial. Neuropsychopharmacology 2012;37:660-668 PMID: 22048460
  • Koola MM, Brown WV, Qualls C, Cuthbert B, Hollis JP, Kelly DL, Le NA, Raines J, Duncan EJ. Reduced arterial compliance in patients with psychiatric diagnoses. Schizophr Res 2012; 137:251-3. PMID: 22377105
  • Gorelick D, Levin KH, Copersino ML, Heishman SJ, Liu F, Boggs DL, Kelly DL. Diagnostic criteria for cannabis withdrawal syndrome. Drug and Alcohol Dependence, 2012:123:141-7. PMID: 22153944
  • Karschner EL, Schwope DM, Schwilke EW, Goodwin RS, Kelly DL, Gorelick DA, Huestis MA. Predictive model accuracy in estimating last D(9)-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug Alcohol Depend 2012;125:313-9. PMID: 22464363.
  • Abrams M, Myers C, McMahon RP, Kelly DL. Cervical cancer screening and associated acute care rates for Medicaid enrollees with mental and substance use disorders. Psychiatric Services, 2012;63:815-22. PMID: 22666450.
  • Kelly DL, Wehring HJ, Vyas G. The current use of clozapine in the US. Shanghai Arch of Psychiatry, 2012;24:110-113.
  • Mackowick KM, Heishman SJ, Wehring HJ, Liu F, McMahon RP, Kelly DL. Illicit drug use in heavy smokers with and without schizophrenia. Schizophr Res, 2012;139:194-200. PMID: 22591779.
  • Wehring HJ, Liu F, McMahon RP, Mackowick KM, Love RC, Dixon L, Kelly DL. Clinical characteristics of heavy and non-heavy smokers with schizophrenia. Schizophr Res 2012:138:285-9. PMID: 22578720
  • Koola M, Wehring HJ, Kelly DL. The potential role of long acting injectable antipsychotics in dually diagnosed people with schizophrenia. Journal of Dual Diagnosis, 2012;8:50-61. PMID: 22754405
  • Abrams MT, Myers CS, Feldman SM, Boddie-Willis C, Park K, McMahon RP, Kelly DL. Cervical cancer screening and acute care visits among Medicaid enrollees with mental and substance use disorders. Psychiatr Serv 2012;63:815-22. PMID: 22660581
  • Koola MM, McMahon RP, Wehring HJ, Liu F, Mackowick KM, Warren KR, Feldman S, Shim JC, Love RC, Kelly DL. Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders. J Psychatriat Res 2012;46:987-93. PMID: 22595870.
  • Kelly DL, Raley H, Lo S, Wright K, Moolchan E, Feldman S, Liu F, McMahon RP, Richardson CM, Jaszyna-Gasior M, Wehring HJ, Boggs D, Heishman S. Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia. Schizophrenia Bull. 2012;38:543-51. PMID: 21041835
  • Jackson J, Eaton W, Cascella N, Fasano A, Warfel D, Feldman D, Richardson C, Vyas G, Linthicum J, Santora D, Warren KR, Carpenter WT, Jr, Kelly DL. A gluten free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies. Schizophr Res 2012;140:262-3. PMID: 22771303
  • Keller WR, Kum LM, Wehring HJ, Koola MM, Buchanan RW, Kelly DL. A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol 2013;27:337-42. PMID: 23151612.
  • Boggs DL, Kelly DL, Liu F, Linthicum J, Turner H, Schroeder JR, McMahon RP, Gorelick DA. Cannabis withdrawal in chronic cannabis users with schizophrenia. J Psychiatr Res 2013;47:340-5. PMID: 23146560
  • Gorelick DA, Goodwin RS, Schwilke E, Schwope DM, Darwin WD, Kelly DL, McMahon RP, Liu F, Ortemann-Renon C, Bonnet D, Huestis MA. Tolerance to Effects of High-Dose Oral [Delta}9-Tetrahydrocannabinol and Plasma Cannabinoid Concentrations in Male Daily Cannabis Smokers. J Anal Toxicol 2013;37:11-6. PMID: 2307421
  • Cascella NG, Santora D, Gregory P, Kelly DL, Fasano A, Eaton WW. Increased prevalence of transglutaminase 6 antibodies in sera from schizophrenia patients. Schizophr Bull 2012, epub ahead of print. PMID: 22516148
  • Warren KR, Buchanan RW, Feldman S, Conley RR, Linthicum J, Ball MP, Liu F, McMahon RP, Gorelick DA, Huestis MA, Kelly DL. Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind pilot study. J Clin Psychopharmacol 2013;33:118-20. PMID: 23277241.
  • Okusaga O, Yolken RH, Langenberg P, Sleemi A, Kelly DL, Vaswani D, Giegling I, Hartmann AM, Konte B, Friedl M, Mohyuddin F, Groer MW, Rujescu D, Postolache TT. Elevate4d gliadin antibody levels in individuals with schizophrenia. World J Biol Psychiatry 2013; epub ahead of print. PMID: 23282016.
  • Lee MR, Wehring HJ, McMahon RP, Linthicum J, Cascella N, Liu F, Bellack A, Buchanan RW, Strauss GP, Contoreggi C, Kelly DL.Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: Results from a randomized double blind placebo controlled pilot study. Schizophr Res. 2013;145:110-5. PMID: 23415472
  • Koola MM, Qualls C, Kelly DL, Skelton K, Bradley B, Amar R, Duncan EJ. Prevalence of childhood physical and sexual abuse in veterans with psychiatric diagnoses. J Nerv Ment Dis 2013;201:348-52. PMID: 23538982